The linear regression equation for pressurised metered-dose inhaler: Using canister weight to predict balance actuation in asthma inhaler

Gobi Hariyanayagam Gunasekaran (gobi_hari@yahoo.com)
Pharmacy Department, Hospital Seri Manjung, Perak, Malaysia. https://orcid.org/0000-0002-2082-9284

Syazwan Faiz b. Kamal Al Arif
Pharmacy Department, Hospital Seri Manjung, Perak, Malaysia.

Shargunan Selvanthan Gunasekaran
Dental Officer, Klinik Pergigian Seri Manjung, Perak, Malaysia.

Sera Selvanthan Sundram Gunasekaran
Medical Officer, Hospital Seri Manjung, Perak, Malaysia.

Short Report

Keywords: Pressurised metered-dose inhaler, linear regression equation

DOI: https://doi.org/10.21203/rs.3.rs-92960/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

INTRODUCTION Pressurised metered-dose inhalers (pMDIs) are not equipped with dose counters hence the balance actuation in a canister could not be determined. Each actuation expels a considerable amount of active ingredients and excipients from a canister, thus the balance actuation remaining in a pMDI based on canister weight could be evaluated using a linear regression equation.

METHODOLOGY New pMDIs of 5 active ingredients [salbutamol (GSK) 200 actuation, budesonide (Glenmark) 300 actuation, ipratropium/fenoterol (Boehringer) 200 actuation, fluticasone (GSK/innovator) 120 actuation, fluticasone (Cipla/generic) 120 actuation, and beclometasone (Ivax) 200 actuation] was weighted. using a laboratory scale (Sartorius R200D; 0.01g accuracy). Two of each pMDI were weighed after each actuation, with a 30-second inter-puff interval, and the mean weight was recorded. To minimise variability in measurements, weighing was limited to one operator. The canister was considered empty when there were no changes in weight after repeated actuation. The prediction equation (one for each pMDI) was the line of best fit through data points on the scatter plot of the number of actuations versus weight.

RESULTS AND DISCUSSION There was low variability between pMDIs weights (SD: 0.03g-0.08g] of the same active ingredients indicating manufacturing uniformity among canisters. Prediction equations were generated for each type of active ingredients, where the general equation is: Actuation remaining = Constant + β*pMDI weight.

CONCLUSION This study produced a prediction equation that can be used to estimate remaining actuation in a pMDI based on its weight. Weighing medication canister could be used to measure actuation remaining in pMDIs, as well as patients’ adherence to pMDIs.

Introduction

Pressurized metered-dose inhalers (pMDI) are the basic method of drug delivery of asthma treatment. The pMDI is an economic and portable medication delivery system, but the device does not indicate how much medicine remains in the canister once a patient starts using it.

The design of metered-dose inhaler makes it impossible for a pMDI to cease delivering drug actuation at an exact point, and the number of actuations in a pMDI need to be more than the recommended actuation. Once the recommended number of medication actuation is expelled, the remaining actuations deliver decreasing concentrations of active medication and increasing concentrations of propellants and excipients.

This study aims to determine if weighing pMDI will be a viable method to determine the remaining dose in the canister. This study could be used as a base to determine if the patient’s pMDI could still be used or exchanged using the weighing method. Exchanging pMDI when necessary could be a cost-saving measure as well.

Aim of the study

This study aimed to prepare a linear regression model of actuation versus weight to determine if weighing pMDI could be used to measure the remaining dose in the canister.

Ethics Approval

Ethical approval for this study was obtained from the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-16-2220-33244)

Methodology
This study was conducted in the pharmacy department, Hospital Seri Manjung. Weighing scale Sartorius R 200 D (±0.001 g) was be used to weigh the canister. New pMDI was used to prepare the linear regression equation. Only the metal canister was weighted (the mouthpiece was removed). The weighing scale was serviced and calibrated by Hospital support service. Data collector was trained to calibrate the weighing machine before each session of data collection.

A data collection form (Form 1: Actuation versus weight monograph) was prepared to collect data on active ingredients, batch number, expiry date, canister weight and actuation. 100 new canisters of each active ingredient from different production batch were weighed to actuation versus weight monograph. Next, 2 new pMDI canisters from each active ingredients were weighed after one actuation, with a 30-second inter-puff interval. To minimise variability in measurements, weighing was limited to one operator. The canister was considered empty when there were no changes in weight after repeated actuation. The prediction equation of one for each pMDI was the line of best fit through data points on the scatter plot of the number of actuations versus weight.

**Result And Discussion**

50 new canisters from each active ingredient were weighed. There is variation in new canister weight between active ingredient (Table 1) and within active ingredients (Table 2).

| Canister               | Manufacturer  | Strength (mcg) | Mean (g) | Std.Dev (g) | Mean weight of actuation (g) | Actuation (Std.Dev) |
|------------------------|---------------|----------------|----------|-------------|-----------------------------|---------------------|
| Salbutamol             | GlaxoSmithKline | 100            | 28.65    | 0.033       | 0.075                       | 1                   |
| Budesonide             | Glenmark      | 200            | 18.23    | 0.083       | 0.03                        | 3                   |
| Ipratropium/Fenoterol  | BoehringerIngelheim | 20/50         | 25.34    | 0.053       | 0.05                        | 1                   |
| Fluticasone (GSK)      | GlaxoSmithKline | 125            | 18.8     | 0.035       | 0.07                        | 1                   |
| Fluticasone (Cipla)    | Cipla         | 125            | 21.11    | 0.076       | 0.075                       | 1                   |
| Beclomethasone         | Ivax          | 100            | 26.78    | 0.042       | 0.08                        | 1                   |

The standard deviation of actuation was obtained by dividing the standard deviation of the canister with mean actuation weight. All new canisters have a deviation of 1 actuation except budesonide which have a deviation of 3 actuation. The deviation of actuation was constant (n=1) win each active ingredients except for budesonide which had a deviation of 3-4 actuation according to different batches.
Table 2 Mean weight of each actuation between different batches according to active ingredients canister

| Canister      | Batch Num  | Num | Mean (g) | Std.dev (g) | Mean weight of actuation (g) | Std.Dev of actuation |
|---------------|------------|-----|----------|-------------|-----------------------------|----------------------|
| Salbutamol    | NN0242     | 30  | 28.66    | 0.033       | 0.075                        | 1                    |
|               | EX2X       | 30  | 28.65    | 0.037       | 0.075                        | 1                    |
|               | NN0241     | 40  | 28.64    | 0.029       | 0.075                        | 1                    |
| Budesonide    | 12170220   | 20  | 18.23    | 0.065       | 0.3                          | 3                    |
|               | 12160693   | 20  | 18.21    | 0.100       | 0.3                          | 4                    |
|               | 12170220   | 20  | 18.22    | 0.100       | 0.3                          | 4                    |
|               | 12160670   | 40  | 18.25    | 0.069       | 0.3                          | 3                    |
| Ipratropium/Fenoterol | 703765 | 20  | 25.29    | 0.037       | 0.05                         | 1                    |
|               | 701750     | 80  | 25.35    | 0.048       | 0.05                         | 1                    |
| Fluticasone (GSK) | A55X    | 50  | 18.79    | 0.040       | 0.07                         | 1                    |
|               | A43Y       | 50  | 18.80    | 0.027       | 0.07                         | 1                    |
| Fluticasone (Cipla) | GB71038 | 20  | 21.11    | 0.061       | 0.075                        | 1                    |
|               | GB71037    | 30  | 21.05    | 0.066       | 0.075                        | 1                    |
|               | GB71032    | 60  | 21.12    | 0.077       | 0.075                        | 1                    |
| Beclometasone | AES75T     | 20  | 26.76    | 0.044       | 0.08                         | 1                    |
|               | AEY36A     | 80  | 26.78    | 0.041       | 0.08                         | 1                    |

Although there was variation in starting weight among new canister and variation between batched among all the active ingredients, the variation of 1-3 actuation is small. This implies that there is a good uniformity among the starting weight of new canister.

To prepare a liner model of actuation versus weight, the weight of canister was measured after each actuation. The canister is considered empty when there were no weight changes after the last actuation.
Table 3 Description of canister weight and number of actuation according to canister active ingredients

| Canister       | Full canister weight | Empty canister weight | Content weight | Manufacturer recommended actuation | Total Actuation | Hypothetical actuation | Mean actuation weight (g) (95% CI) |
|----------------|----------------------|-----------------------|----------------|------------------------------------|-----------------|------------------------|-----------------------------------|
| Salbutamol     | 28.71                | 12.13                 | 16.58          | 200                                | 235 (17.5)      | 221 (10.5)             | 0.075 (0.07-0.078)                |
| Budesonide     | 18.17                | 9.015                 | 9.155          | 300                                | 305 (1.7)       | 305 (1.7)              | 0.03 (0.029-0.031)                |
| Ipra/Fenoterol | 25.22                | 12.55                 | 12.67          | 200                                | 247 (23.5)      | 253 (26.5)             | 0.05 (0.0502-0.0523)              |
| Fluticasone (GSK) | 18.81               | 7.9                   | 10.91          | 120                                | 152 (21.3)      | 156 (30)               | 0.07 (0.0685-0.0718)              |
| Fluticasone (Cipla) | 21.04              | 9.71                  | 11.33          | 120                                | 152 (21.3)      | 151 (25.8)             | 0.075 (0.073-0.076)               |
| Beclometasone  | 26.75                | 9.73                  | 17.02          | 200                                | 218 (9)         | 213 (6.5)              | 0.078 (0.0769-0.0794)             |

a. The mean weight of new 2 canister
b. The mean weight of 2 empty canisters from (a)
c. The manufacture recommended actuation according to the product leaflet
d. Hypothetical actuation is calculated by canister content divided by mean actuation weight

All canisters could be actuated past the manufacture recommended actuation (Table 3). Budesonide had the least amount of excess actuation (1.7%) and Fluticasone had the most amount of excess actuation (21.3%). Our finding correlates with a study by Brock\(^2\) which showed that additional actuations were released canister in their study as well. Brock's study compared to our study showed that the excess from Ipratropium/Fenoterol was (27.5% vs 23.5%), Fluticasone (24.2% vs 21.3%), and Salbutamol (9.5% vs 17.5%).

A hypothetical actuation was calculated (Table 3) to compare with manufactures recommended actuation and the total actuation released from the canister. Hypothetical actuation was calculated by full canister weight with empty canister weight to get the content weight. The content weight was divided with mean actuation weight to predict the amount of hypothetical actuation in each canister. There was a linear correlation between total actuation, hypothetical actuation and manufacturer recommended actuation. The correlation is strongest between total actuation and hypothetical actuation (\(r=0.995, p<0.001\)) compared to manufacturer-recommended actuation and hypothetical actuation (\(r=0.970, p<0.001\)). This finding suggests that each canister could be actuated past manufacturer's recommendation similar with a study by Talasila\(^3\) to investigate the effect of extra actuation on dose delivery showed that canister should be packaged with extra actuation of 15-30% to deliver the required 200 metered dose as marketed by manufacturer.
Table 4 compared the mean weights of the Salbutamol (GSK) obtained from a study done in European country\textsuperscript{10} with our finding. There was a linear correlation between the mean weights of both canisters measured on the study (r = 1, p<0.0001). This finding shows that although the canister was acquired from the different region the weight of canister at various actuations is similar.

The amount of active ingredients in those additional actuations is variable as propellant and excipients form up to 99% of an asthma drug formulation\textsuperscript{5}. Currently, available MDI are formulated as suspensions. Suspensions comprise micronized drug substance suspended in propellant and other excipients (Figure 1). If the drug substance adheres to the walls of the container or valve components, dose delivery and particle size distribution could be inconsistent\textsuperscript{5,6}. Actuating beyond the recommended number of actuation will cause the active ingredient delivery per actuation becomes unpredictable, a phenomenon is known as “tail-off”\textsuperscript{7} (Figure 2). Tail-off is particularly problematic when the medication delivered by the MDI is formulated as a suspension rather than a solution. Tail-off may be rapid (e.g., within 5 actuations), or erratic, requiring 10–20 actuations before the canister is finally empty of its drug content\textsuperscript{8}.

The phenomenon “tail-off” was also observed in this study when the canister was actuated post manufactures recommendation. The ‘tail off’ could be observed from Salbutamol (Figure 3) at actuation 223 (23 actuation more than recommended), Ipratropium/Fenoterol (Figure 5) from actuation 233 (33 more than manufacturer recommendation), Fluticasone-GSK (Figure 6) from actuation 143 (23 more than recommended), Fluticasone-Cipla (Figure 7) from actuation 147 (27 more than recommended) and Beclometasone (Figure 8) from actuation 202 onwards. ‘Tail off’ phenomena was not observed for Budesonide canister (Figure 4) as there was no more puff expulsion after 305 actuation (5 more than recommended).

Advising the patient to use the inhaler until it is empty or more than the recommended actuation will not guarantee the accurate actuation of medication will be delivered to the patient. Although there might be some solution in the canister or visible puff could be seen after each actuation, the amount of recommended active ingredients will not be accurate. All manufacturer recommended that the accurate actuation of medication from MDI can only be ensured if the patient uses the recommended number of actuation.
Actuating the canister until its empty might be patient an important contributor to poor asthma control. For example, patients may think they are taking their asthma medication when they inhaling excipients and sub-therapeutic active ingredients. This is potentially dangerous especially for rescue medication such as Salbutamol.

**Linear regression model to predict the number of actuation from weight**

A linear regression model to predict the number of actuation from weight was created. The model was created by weighing the canister after each actuation.

A linear regression model to predict the number of actuation from weight was created. The model was created by weighing the canister after each actuation.

| Table 5: Coefficients of Linear regression |
|-------------------------------------------|
| Canister model | Unstandardized Coefficients | Standardized Coefficients | t | Sig. | 95% Confidence interval for B |
|                | B | Std. Error | Beta |     |       | Lower Bound | Upper Bound |
| Salbutamol (GSK) (Constant) | 391.244 | .072 | 1.000 | 5459.897 | .000 | 391.103 | 391.385 |
| Canister_weight | -13.603 | .003 | 1.000 | -400.936 | .000 | -13.610 | -13.596 |
| Budesonide(Glenmark) (Constant) | 597.477 | .285 | 1.000 | 2093.731 | .000 | 596.916 | 598.039 |
| Canister_weight | -32.956 | .021 | 1.000 | -158.975 | .000 | -32.997 | -32.915 |
| Ipratropium/Fenoterol (Boehringer) (Constant) | 477.499 | .123 | 1.000 | 3788.449 | .000 | 477.251 | 477.747 |
| Canister_weight | -18.932 | .060 | 1.000 | -292.081 | .000 | -18.944 | -18.919 |
| Fluticasone (GSK), (Constant) | 260.534 | .279 | 1.000 | 934.067 | .000 | 259.983 | 261.085 |
| Canister_weight | -13.892 | .020 | 1.000 | -68.072 | .000 | -13.932 | -13.851 |
| Fluticasone (Cipla) (Constant) | 279.938 | .106 | 1.000 | 2628.820 | .000 | 279.728 | 280.148 |
| Canister_weight | -13.295 | .007 | 1.000 | -19.595 | .000 | -13.308 | -13.281 |
| Beclometasone (Ivax). (Constant) | 388.576 | .120 | 1.000 | 2829.239 | .000 | 338.341 | 338.812 |
| Canister_weight | -12.687 | .006 | 1.000 | -20.340 | .000 | -12.700 | -12.675 |

Dependent Variable: Actuation

There was a significant linear relationship between actuation and canister weight for the canister measured. The linear relationship for Salbutamol was (b=-13.6, 95%CL [-13.61,-13.596], p<0.0001, \( r^2=1.0 \)). The number of actuation could be predicted from weight by the following formula: Actuation = 391.0244+ (-13.6*canister_weight).

The linear relationship for Budesonide was (b=-32.956, 95%CL [-32.997,-32.915], p<0.0001, \( r^2=1.0 \)). Number of actuation could be predicted from weight by the following formula: Actuation = 597.477+ (-32.96*canister_weight).

The linear relationship for Ipratropium/Fenoterol 20/50mg was (b=-18.932, 95%CL [-18.944,-18.919], p<0.0001, \( r^2=1.0 \)). Number of actuation could be predicted from weight by the following formula: Actuation = 477.499+ (-18.932*canister_weight).
The linear relationship for Fluticasone (GSK) was \( (b=-13.892, 95\% CL [-13.932,-13.851], p<0.0001, r^2=1.0) \). Number of actuation could be predicted from weight by the following formula: Actuation = 260.534 + (-13.892*canister\_weight).

The linear relationship for Fluticasone (Cipla) was \( (b=-13.295, 95\% CL [-13.308,-13.281], p<0.0001, r^2=1.0) \). Number of actuation could be predicted from weight by the following formula: Actuation = 279.938 + (-13.295*canister\_weight).

The linear relationship for Beclometasone was \( (b=-16.687, 95\% CL [-12.7,-12.675], p<0.0001, r^2=1.0) \). Number of actuation could be predicted from weight by the following formula: Actuation = 338.576 + (-12.687*canister\_weight).

Conclusion

There was low variability between pMDIs weights (SD: 0.03g-0.08g) as well as the minimal difference between 1-3 actuation among new canister and difference between 1-4 actuation between batched of each active ingredients indicating manufacturing uniformity among. Each canister could be actuated past manufacturer recommendation with Budesonide had the least amount of excess actuation (1.7%) and Fluticasone had the most amount of excess actuation (21.3%). Prediction equations were generated for each type of active ingredients, where the general equation is: Actuation remaining = Constant + \( \beta \)\*pMDI weight. Weighing pMDI could be used as a dose counter at health care facilities; however, it must be noted that there will be a unique relationship between each product.

Declarations

Conflicts of interest

The authors declared that they have no conflict of interest.

Funding Statement.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgement

The authors would like to thank the Director-General of Health Malaysia for his permission to publish this article. The authors are thankful to the team of our study and to the pharmacy department, Hospital Seri Manjung who supported in all aspect to conduct this study.

References

1. Sander N, Fusco-Walkert SJ, Harder JM, Chipps BE. Dose counting and the use of pressurized metered-dose inhalers: Running on empty. Ann Allergy Asthma Immunol 2006; 97:34–38.
2. Brock TP, Wessell AM, Williams DM, Donohue JF. Accuracy of float testing for metered-dose inhaler canisters. Journal of the American Pharmaceutical Association (1996). 2002 Aug 31;42(4):582.
3. Talasila GK, Mukkala BV, Vattikuri S. Formulation and evaluation of CFC free inhalers for beclomethasone dipropionate. Brazilian Journal of Pharmaceutical Sciences. 2013 Jun;49(2):221-31.
4. Di Paolo ER, Spaggiari S, Pannatier A, Sadeghipour F, Rochat I, Hafen GM. Stop using the flotation technique and start weighing Salbutamol pressurised metered-dose inhalers without dose counters. Swiss Med Wkly. 2015 Jul 31;145:w14162
5. Jinks P, Hunt K. Improving suspension MDI dose consistency in patient use by incorporation of a novel semi-permeable system component. Proceedings of Drug Delivery to the Lungs XVII, The Aerosol Society, Portishead, United Kingdom. 2006:172-5.

6 Dunn TJ, Baguley T, Brunsden V. From alpha to omega: A practical solution to the pervasive problem of internal consistency estimation. British Journal of Psychology. 2014 Aug 1;105(3):399-412.

7. Holt S, Holt A, Weatherall M, Masoli M, Beasley R. Metered dose inhalers: A need for dose counters. Respirology 2005; 10:105-106

8. Schultz RK. Drug delivery characteristics of metered-dose inhalers. Journal of allergy and clinical immunology. 1995 Aug 31;96(2):284-7.